| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Propranolol has recently been shown to be highly effective for infantile hemangiomas (IHs). However, the therapeutic mechanism of action of propranolol and the usefulness of measurement of vascular endothelial growth factor (VEGF) remains poorly understood. This study aimed to determine the efficacy of propranolol treatment on various features and to evaluate changes in plasma VEGF levels in patients with IH who underwent propranolol treatment.The study group consisted of 35 children with IH. Oral propranolol was administered at a dose of 2.0 mg/kg/day and was divided in three doses. Plasma VEGF concentrations were analyzed by enzyme-linked immunoabsorbent assay, and the values between the groups were compared. VEGF concentrations 4 weeks after treatment were significantly lower than those before treatment (p < 0.01). We conclude that measurement of VEGF may be a useful tool for predicting the course of hemangioma and monitoring the effectiveness of treatment.
|
